Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES002023 in Advanced Solid Tumors
NCT05075564Phase 1Completed
- Sponsor
- Elpiscience
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of eurestobart in solid tumor (advanced stage), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Elpiscience. Primary endpoints: Frequency and severity of adverse events of ES002023 and Maximum Tolerated Dose, Optimal Biological Dose and/or Recommended Phase 2 Dose. Started Dec 2021; status: completed.
02
Drugs
eurestobart
03
Conditions
solid tumor (advanced stage)pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT05075564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075564.